Rollins, Inc. · ROL · FY2026 Q2 · Calendar Q3 2026
Rollins Q2 2026: Revenue Misses as Digital Lead Slowdown Hits Orkin
Rollins' Q2 2026 results fell short of consensus on both lines, with revenue of $1.08B (up 7.9% YoY, organic 5.7%) missing by ~1.4% and EPS of $0.32 missing by ~4.7%. The shortfall was concentrated in digitally-initiated residential demand at Orkin, a sharp contrast to Q1's 10.2% revenue growth and 6.6% organic growth. Management lowered full-year organic growth guidance from 7-8% to at least 6% while introducing a minimum 10% incremental margin commitment. The stock declined ~8% on 3.6x baseline volume. Multi-brand diversification through HomeTeam and Fox provided partial resilience with double-digit residential growth, and M&A including the Romex acquisition continues to contribute 2-3% of revenue growth, but the digital lead generation slowdown and its potential connection to AI/LLM search disruption introduce a new layer of uncertainty.
Company context
Snapshot as of publicationRollins, Inc. operates a network of subsidiaries that specialize in delivering pest and wildlife management solutions to a diverse clientele, encompassing both homeowners and commercial enterprises, throughout the United States and globally. For residential properties, the company offers comprehensive pest control, safeguarding homes from prevalent invaders such as rodents, insects, and other nuisance animals. Furthermore, it devises tailored pest management strategies for various business sectors, including healthcare, foodservice, and logistics. Beyond standard pest solutions, Rollins, Inc. also provides a range of termite defense options, from conventional treatments to baiting systems, alongside other complementary services. The firm serves its customers directly through its own operations as well as through its extensive franchisee network. Established in 1948, Rollins, Inc. maintains its headquarters in Atlanta, Georgia.
Earnings scorecard
Reported versus consensusEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Underweight | Equal Weight | Downgrade | Jul 24, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 24, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 24, 2026 |
| JP Morgan | Neutral | Overweight | Downgrade | Jul 24, 2026 |
| Canaccord Genuity | Hold | Hold | Maintain | Jul 24, 2026 |
| BNP Paribas | Neutral | Neutral | Maintain | Jul 24, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jul 24, 2026 |
| RBC Capital | Sector Perform | Outperform | Downgrade | Jul 23, 2026 |
| B of A Securities | Underperform | Buy | Downgrade | Jul 23, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 8, 2026 |
| Bernstein | Market Perform | Outperform | Downgrade | May 29, 2026 |
| Jefferies | Buy | Hold | Upgrade | Jun 2, 2025 |
| Stifel | Buy | Hold | Upgrade | Oct 20, 2023 |
| Buckingham Research | Neutral | Neutral | Maintain | Feb 4, 2020 |
| Buckingham | Neutral | Neutral | Maintain | Feb 4, 2020 |
| Stifel Nicolaus | Hold | Sell | Upgrade | Nov 6, 2019 |
| Nomura | Buy | Buy | Maintain | Apr 30, 2019 |
| Macquarie | Neutral | Neutral | Maintain | Apr 30, 2019 |
| William Blair | Outperform | Outperform | Maintain | Jan 30, 2018 |
| Sidoti & Co. | Neutral | Buy | Downgrade | Mar 21, 2016 |
| KeyBanc | Hold | Hold | Maintain | Apr 17, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $38.35. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Joshua Chan | $43 | $38.59 | +12.1% | Jul 24, 2026 |
| Barclays | Analyst unavailable | $45 | $39.44 | +17.3% | Jul 24, 2026 |
| Wells Fargo | Jason Haas | $32 | $39.44 | -16.6% | Jul 24, 2026 |
| Canaccord Genuity | Analyst unavailable | $45 | $38.62 | +17.3% | Jul 23, 2026 |
| Raymond James | Analyst unavailable | $35 | $43.47 | -8.7% | Jul 23, 2026 |
| RBC Capital | Ashish Sabadra | $40 | $43.47 | +4.3% | Jul 23, 2026 |
| UBS | Analyst unavailable | $50 | $44.29 | +30.4% | Jul 15, 2026 |
| Morgan Stanley | Greg Parrish | $65 | $43.62 | +69.5% | Jul 8, 2026 |
| Wells Fargo | Analyst unavailable | $46 | $44.54 | +19.9% | Jun 25, 2026 |
| Bernstein | Connor Cerniglia | $52 | $49.42 | +35.6% | May 29, 2026 |
| Redburn Partners | Analyst unavailable | $66 | $56.6 | +72.1% | Apr 27, 2026 |
| UBS | Analyst unavailable | $61 | $56.16 | +59.1% | Apr 24, 2026 |
| Canaccord Genuity | Analyst unavailable | $51 | $56.99 | +33.0% | Apr 24, 2026 |
| Goldman Sachs | Analyst unavailable | $67 | $56.99 | +74.7% | Apr 23, 2026 |
| UBS | Analyst unavailable | $58 | $54.8 | +51.2% | Apr 10, 2026 |
| Morgan Stanley | Analyst unavailable | $70 | $58.97 | +82.5% | Feb 13, 2026 |
| Canaccord Genuity | Analyst unavailable | $52 | $58.69 | +35.6% | Feb 13, 2026 |
| RBC Capital | Analyst unavailable | $67 | $57.07 | +74.7% | Feb 12, 2026 |
| Wells Fargo | Jason Haas | $56 | $65.6 | +46.0% | Feb 12, 2026 |
| UBS | Analyst unavailable | $65 | $63.11 | +69.5% | Jan 21, 2026 |
| RBC Capital | Ashish Sabadra | $70 | $60.71 | +82.5% | Dec 23, 2025 |
| Morgan Stanley | Toni Kaplan | $72 | $59.46 | +87.7% | Dec 17, 2025 |
| Barclays | Analyst unavailable | $72 | $60.34 | +87.7% | Dec 5, 2025 |
| Jefferies | Stephanie Moore | $66 | $57.61 | +72.1% | Nov 3, 2025 |
| Canaccord Genuity | Analyst unavailable | $55 | $57.79 | +43.4% | Oct 31, 2025 |
| Goldman Sachs | George Tong | $64 | $57.79 | +66.9% | Oct 30, 2025 |
| Wells Fargo | Analyst unavailable | $63 | $56.28 | +64.3% | Oct 28, 2025 |
| Goldman Sachs | George Tong | $61 | $55.47 | +59.1% | Apr 24, 2025 |
| Barclays | Analyst unavailable | $55 | $52.21 | +43.4% | Apr 4, 2025 |
| Barclays | Manav Patnaik | $50 | $47.86 | +30.4% | Nov 4, 2024 |
| Wells Fargo | Jason Haas | $54 | $47.78 | +40.8% | Aug 12, 2024 |
| Stifel Nicolaus | Michael Hoffman | $54 | $49.75 | +40.8% | Jun 20, 2024 |
| UBS | Joshua Chan | $49 | $44.35 | +27.8% | Apr 15, 2024 |
| RBC Capital | Ashish Sabadra | $52 | $43.8 | +35.6% | Jul 13, 2023 |
Track every rating change on ROL the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session closeFollow ROL with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
The most significant shift from Q1 to Q2 was the deceleration in digitally-initiated residential pest-control demand, particularly at Orkin, which drove both the revenue and EPS miss. Q1 revenue grew 10.2% with 6.6% organic growth and a confident management tone (bullish score 78); Q2 revenue grew 7.9% with 5.7% organic growth and a cautious management tone (bullish score 65). Margin pressure sources shifted from insurance, claims, and fleet costs in Q1 to medical costs, fuel, and SG&A in Q2. Full-year organic growth guidance was reduced from 7-8% to at least 6%, though a new minimum 10% incremental margin target was introduced. New CFO William Harkins made his first earnings call appearance, and Scott Weaver was promoted to COO overseeing both residential and commercial operations in the U.S. and Canada. Management also flagged for the first time the potential impact of AI and large-language-model search results on digital lead generation.
Guidance delta
Full-year organic revenue growth guidance was lowered from 7-8% to at least 6%. The company introduced a minimum 10% incremental margin commitment as a new guidance element. M&A contribution of 2-3% of revenue growth was maintained. The transcript analysis classified overall guidance sentiment as raised, reflecting the addition of the incremental margin target even as the organic growth floor was reduced.
Key takeaways
- Q2 revenue of $1.08B grew 7.9% YoY (organic 5.7%) but missed consensus by ~1.4%; EPS of $0.32 missed by ~4.7%.
- Digital lead generation slowdown at Orkin drove the revenue miss, while HomeTeam and Fox posted double-digit residential growth.
- Termite, ancillary, and commercial segments delivered solid double-digit gains, partially offsetting residential softness.
- Margin pressure from higher medical costs, fuel expenses, and SG&A, but incremental margin guidance maintained at 10% or higher.
- Full-year organic growth guidance updated from 7-8% to at least 6%; M&A contribution of 2-3% maintained.
- Romex acquisition completed in Q2 as Rollins' largest Q2 acquisition, alongside several tuck-in deals.
Management priorities
- Implement organizational and operational changes to improve accountability and resource alignment across residential and commercial operations.
- Leverage new fleet supplier agreement with Wheels to reduce fleet costs.
- Continue procurement initiatives to capture cost savings across the business.
- Monitor and adjust digital marketing and SEO strategies, including the potential impact of AI and large-language-model search on lead generation.
- Pursue disciplined M&A opportunities to meet the 2-3% revenue growth contribution target.
- Accelerate cross-selling of ancillary services across all brands.
Related earnings events
IndustrialsSources
- Earnings call transcript and parsed analysis · 2026-07-23T15:03:37.539953+00:00
- FN2 earnings calendar · 2026-07-31T01:23:16.182055+00:00
- Polygon adjusted daily market bars · 2026-07-31T04:31:10.178247+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T04:31:10.176138+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.